Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tonghua Dongbao Out-Licenses US Rights for Three Insulin Biosimilars to Meitheal

publication date: Sep 22, 2023

Tonghua Dongbao Pharma (THDB) out-licensed US commercialization rights for three insulin biosimilars — insulin aspart, insulin lispro, and insulin glargine — to Meitheal Pharma of Chicago. Meitheal is a division of Nanjing King-Friend Biochemical Pharmaceutical (NKF). THDB and NKF will be jointly responsible for the development and supply of the three products. In an unusual arrangement, all three companies, THDB, NKF and Meitheal, will receive royalties on US product sales. Details of the agreement were not disclosed. THDB expects the three products will be approved for US use in 2026. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital